Tags : Nanobiotix

Weekly Snapshot

PharmaShots Weekly Snapshots (Jan 18 – 22, 2021)

Takeda’s Alunbrig (brigatinib) Receives MHLW’s Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC Published: Jan 22, 2020 | Tags: Takeda, Alunbrig, (brigatinib), Receives, MHLW, Approval,1L and 2L, Treatment, ALK+ Advanced or Recurrent NSCLC MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the […]Read More

Pharma

Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and

Shots: Nanobiotix launches a new subsidiary, Curadigm along with its Nanoprimer technology to reshape the balance b/w bioavailability, toxicity, and efficacy in the healthcare system in France & the US Nanobiotix will remain focus on its lead candidate NBTXR3 to expand radiotherapy benefits and its Immuno-Oncology program to innovate cancer immunotherapies and has also received […]Read More